CAS 55778-02-4: 1,4-Benzenedimethanamine, N,N'-di-2-pyridinyl-

WZ811

WZ811 is a novel and effective small molecular CXCR4 antagonist (EC50: 0.3 nM).

WZ811 is a small-molecule drug that has been shown to have therapeutic effects in a number of autoimmune diseases, such as bowel disease and multiple sclerosis. It binds to chemokine receptors on the surface of immune cells and blocks the binding of chemokines, preventing the release of inflammatory cytokines. WZ811 also prevents neuronal death by inhibiting toll-like receptor 4 (TLR4) signaling pathways. WZ811 has not been tested in humans yet but has shown promising results in vitro assays and in animal models. The compound is being studied for its potential use as a diagnostic agent for brain cancer. This drug has not been tested for toxicity or side effects with regards to HIV infection or other blood disorders.